Formulation Development
Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy
Daré Bioscience, Inc. recently announced the initiation of a Phase 1 clinical trial of DARE-HRT1, designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over…
LGM Pharma Acquires Pharmaceutical Development & Manufacturing Unit of Nexgen Pharma
LGM Pharma recently announced it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The combination brings together LGM…
Oculis Announces Successful End-of-Phase 2 Meeting With the FDA
Oculis S.A. recently announced it has successfully completed an End-of-Phase 2 meeting with the US FDA for OCS-01 in two indications: for the treatment of…
Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions has recently signed an agreement with Moleculin Biotech, Inc., to support the company’s expanded development…
DalCor Announces dal-GenE Trial Continues With Final Data Expected in the First Half of 2021
DalCor Pharmaceuticals recently announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with…
Frontage Laboratories 2020 Podcast Series
Welcome to Frontage Laboratories 2020 Podcast Series. Listen to our full suite of podcasts of engaging topics from our top scientific experts.
Croda Strengthens Position in Life Sciences With Acquisition of Avanti Polar Lipids
Croda International Plc recently announced it has agreed to acquire Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals…..
Don’t Miss RNA Medicine in a Pandemic Symposium on July 23!
Join us as we are hosting an RNA Symposium bringing together leading experts in RNA medicine, delivery, technology development, and solutions for manufacturing to present and discuss…
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services
Lonza Pharma & Biotech recently announced the establishment of a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its Bend, OR, site…..
SGS Joins Biophytis to Launch International Clinical Trial of COVID-19-Related Respiratory Failure Treatment
SGS has recently received approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) and has initiated the first site to begin a new clinical trial of….
ABITEC Corporation Acquires Larodan AB Research-Grade Lipids
ABITEC Corporation, an ABF Ingredients company, announced today that it has acquired Larodan AB, a manufacturer and international marketer of state of the art, high-purity research grade lipids…..
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan
Apellis Pharmaceuticals, Inc. recently announced the completion of enrollment in the global Phase 3 PRINCE study, which is evaluating pegcetacoplan (APL-2) in….
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero & Boston Biomedical
Sumitomo Dainippon Pharma Oncology, Inc. was recently formed through the merger of Tolero Pharmaceuticals, Inc., and Boston Biomedical, Inc., two clinical-stage companies developing novel….
Lonza Expands Particle Engineering Assets to Advance Complex Molecules
Lonza reecently announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities. Jet milling and spray dry processing for development…
Cambrex Increases Flexible Manufacturing Capacity
Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, recently announced it is investing $3.6…
IM Therapeutics Announces First Patient Dosed in Phase 1 Study of its Lead Drug for Type 1 Diabetes
ImmunoMolecular Therapeutics, Inc. recently announced the dosing of the first patient in a Phase 1 study of IMT-002, an oral small molecule drug designed as a selective….
Timber Pharmaceuticals Announces All CONTROL Study Sites Open & Enrolling Patients With Moderate-to-Severe Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced that all 11 sites across the US and Australia participating in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) are now….
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products
Geron Corporation recently announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan…
MediciNova Announces Opening of IND for MN-166 for Prevention of Acute Respiratory Distress Syndrome in Patients With COVID-19
MediciNova, Inc. recently announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for prevention of Acute Respiratory Distress Syndrome (ARDS) has been accepted…
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42 Million
Avadel Pharmaceuticals plc recently announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep,…
